• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Japan·Healthcare·4540.T
Share

Tsumura & Co. Stocks

¥ 3711Last Updated 10.09.2026

Issuer Rating

7/7
Performance

Strong

Risk

Low

Recommendation

Buy

Market Cap

¥ 1.77B

¥ 3711
Key Takeaways

Risk factor

Negligible price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Established in Tokyo, Japan, in 1893, Tsumura & Co. operates worldwide in the pharmaceutical sector. The company's core business involves the creation and international distribution of various medicinal products, with a particular focus on Kampo extract intermediates and granular Kampo preparations. Its operations are comprehensive, encompassing the full supply chain: from the careful acquisition, selection, processing, and warehousing of raw herbal materials and crude drug components for decoctions, to the manufacturing of powdered Kampo extracts and traditional Chinese medicines. Additionally, Tsumura & Co. is engaged in the sale of both pharmaceutical goods and food products.

Company Valuation

Greatly undervalued
7/7

Based on key historical and expected multiples, the stock is greatly undervalued relative to its peers. In particular, the stock is underpriced on P/E, 'cheap' on EV/EBIT

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Somewhat favourable
5/7

The average target price of 4540.T is 4503 and suggests 22.8% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to in

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

12.09.2026 16:01

Small caps last week: Chewy's earnings miss, Signet's best day ever, AE rethinks ads

12.09.2026 13:01

The iPhone Reboot, the AGI Era, and Silicon Valley's Right Turn

12.09.2026 05:06

Spam from OpenAI's AI agents disrupted the developer service for four days

12.09.2026 03:52

Citrini, the founder who spooked the market with his prediction of AI threats, has sold the company. What's next?

12.09.2026 03:18

Dell's stock reached an all-time high. Dell has joined the ranks of the world's top three richest people

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026